NCT01722149View on ClinicalTrials.gov

Re-directed T Cells for the Treatment (FAP)-Positive Malignant Pleural Mesothelioma

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

February 19, 2015

Primary Completion Date

March 22, 2019

Study Completion Date

July 18, 2019

Conditions
Malignant Pleural Mesothelioma
Interventions
GENETIC

Adoptive Transfer of re-directed T cells

Adoptive Transfer of 10e6 re-directed T cells in the pleural effusion

Trial Locations (1)

8091

University Hospital Zurich, Division of Oncology, Zurich

All Listed Sponsors
lead

University of Zurich

OTHER

NCT01722149 - Re-directed T Cells for the Treatment (FAP)-Positive Malignant Pleural Mesothelioma | Biotech Hunter | Biotech Hunter